Clinical Trials in the USA / NCT05297500
Active, not recruiting
Observational
Determination of SpO2 and PR Accuracy Specifications at Rest (71Ag_Vital-0031)
NCT05297500 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Hypoxia
Investigational drug(s) / intervention(s)
Pulse oximeter
Pulse oximeter: OLV-4202 pulse oximeter (SW version: 01-12)
Study summary
The aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling. Study will be used with patients at rest
Eligibility
Inclusion Criteria:
* Both male and female subjects who can give written informed consent
* Healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile
* Meeting the demographic requirements
Exclusion Criteria:
* Pregnant women
* Significant arrhythmia
* Blood pressure above 150 systolic or 90 diastolic
* Carboxyhemoglobin levels over 3%
* Subjects whom the investigator consider ineligible for the study
Primary outcome measure(s)
- Root-mean-square (Rms) of device SpO2 measurement with room air stabilization is within +-2% [%SpO2] of reference co-oximeter SaO2 measurement at varying desaturation levels (70% to 100%) — 30 minutes
Each subject will have an arterial catheter inserted in the left or right wrist and the pulse oximeter study device placed on different fingers of the left or right hand, or the left or right earlobe or the forehead. Measurement position is randomized across subjects. For each subject, a series of desaturation runs are performed. Run 1 stabilized room air period -\> stabilized plateaus at saturation level targets: room air, 92%, 87%, 82%, 77%, 72% Run 2 stabilized 100% O2 period -\> stabilized plateaus at saturation level targets: 100%, 93%, 88%, 83%, 78%, 73% SpO2 is observed breath by breath arterial saturation, which is in turn computed from end tidal PO2 and PCO2. FiO2 is reduced suddenly at first then adjusted to achieve a stable plateau value at the desired target. Each desaturation plateaus should not exceed 10 minutes. A blood draw is taken at stable FiO2 and +30 seconds. The gas mixture is then changed for the next value and repeated for each plateau value. - Root-mean-square (Rms) of device Pulse Rate measurement with room air stabilization is within +-3 [1/min] of reference ECG Pulse Rate measurement at heart rates (30 to 300 [1/min]) — 30 minutes
Each subject will have an arterial catheter inserted in the left or right wrist and the pulse oximeter study device placed on different fingers of the left or right hand, or the left or right earlobe or the forehead. Measurement position is randomized across subjects. For each subject, a series of desaturation runs are performed. Run 1 stabilized room air period -\> stabilized plateaus at saturation level targets: room air, 92%, 87%, 82%, 77%, 72% Run 2 stabilized 100% O2 period -\> stabilized plateaus at saturation level targets: 100%, 93%, 88%, 83%, 78%, 73% Pulse rate is recorded from the test device and from the reference ECG monitor. PR data measurements are gathered during the stable plateau value at the desired saturation target. Each desaturation plateaus should not exceed 10 minutes. The gas mixture is then changed for the next value and repeated for each plateau value.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| UCSF Hypoxia Research Laboratory | San Francisco | California |
More Nihon Kohden trials in the USA
Pulse Oximeter Accuracy During Stable Hypoxia Plateaus
Active, not recruiting
Comparison of Noninvasive vs. Invasive Hemodynamic Measurements
Active, not recruiting
SpO2 Accuracy in Children
Enrolling by invitation
Other trials for the same condition
Pulse Oximeter Accuracy During Stable Hypoxia Plateaus
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05297500 on ClinicalTrials.gov ↗ ← All trials in the USA